Abstract: A tissue-specific manganese based magnetic resonance imaging (MRI) agent includes the formula: wherein T includes at least one cell specific or tissue specific targeting moiety; C includes at least one pyclen based chelating agent complexed with a Mn ion, and L includes at least one optional linker that covalently links the at least one targeting moiety to the at least one chelating agent.

Abstract: A compound comprising formula (I): wherein R1 is an alkylamino group or a group containing at least one aromatic group; R2 and R3 are independently an aliphatic group or hydrophobic group; R4 and R5 are independently H, a substituted or unsubstituted alkyl group, an alkenyl group, an acyl group, an aromatic group, polymer, a targeting group, or a detectable moiety; a, b, c, and d are independently an integer from 1 to 10; and pharmaceutically acceptable salts thereof.

Abstract: A method of detecting drug-resistant cancer in a subject is described. The method includes contacting a tissue of the subject with an effective amount of a molecular probe, detecting the amount of the molecular probe present in the tissue, comparing the amount of molecular probe detected to a control value, and detecting drug-resistant cancer in the subject if the amount of the molecular probe present in the tissue is higher than the control value. The molecular probe includes the following formula: P-L-C wherein P is a EDB-FN targeting peptide, C is a contrast agent; and L is a non-peptide linker that covalently links the peptide to the contrast agent. Methods of monitoring the treatment of drug resistant cancer are also described.

Abstract: Molecular probe compounds according to the formula P-L-I are described. P is a targeting peptide selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 117; I is an imaging agent; and L is an optional non-peptide linker that covalently links the peptide to the imaging agent, wherein the linker comprises a carboxylic acid that forms a carboxamide with an amine of the targeting peptide or a maleimide that forms a thioester bond with a cysteine residue of the targeting peptide. Methods of detecting cancer and monitoring the treatment of cancer using the molecular probes are also described.

Abstract: A nanosized complex includes a nucleic acid and a compound comprising formula (I): wherein R1 is an alkylamino group or a group containing at least one aromatic group; R2 and R3 are independently an aliphatic group or hydrophobic group; R4 and R5 are independently H, a substituted or unsubstituted alkyl group, an alkenyl group, an acyl group, or an aromatic group, or a polymer, a targeting group, a detectable moiety, or a linker, or a combination thereof, and at least one of R4 and R5 includes a retinoid or retinoid derivative that targets and/or binds to an interphotoreceptor retinoid binding protein; a, b, c, and d are independently an integer from 1 to 10; and pharmaceutically acceptable salts thereof.

Abstract: An anticancer peptide conjugate is described that comprises the following formula: P-L-A wherein: P is a peptide that includes an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or variants thereof in which one or more L-amino acids have been replace with a corresponding D-amino acid; A is an antitumor agent; and L is an optional linker that covalently links the peptide to the antitumor agent, and pharmaceutically acceptable salts thereof. Methods of using the anticancer peptide conjugates to treat cancer are also described.

Abstract: A molecular probe includes the following formula: P-L-C wherein P is a EDB-FN targeting peptide, C is a contrast agent; and L is a non-peptide linker that covalently links the peptide to the contrast agent.

Abstract: A plasmid vector comprising one or more heterologous nucleic acids or genes encoding a functional therapeutic protein configured to treat a retinal or ocular includes a human GRK1 promoter and human S/MAR enhancer to express the heterologous gene in both rod and cone photoreceptors.

Abstract: A pharmaceutical composition includes a retinylamine derivative having the following formula: where R1 is an amino acid residue, a dipeptide or a tripeptide that is linked to the retinylamine by an amide bond.

Abstract: A nanosized complex includes siRNA and a compound comprising formula (I):

Abstract: A molecular probe comprising a linear peptide that includes an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9; a contrast agent; and a non-peptide linker that covalently links the peptide to the contrast agent.

Abstract: A nanosized complex includes siRNA and a compound comprising formula (I):

Abstract: A compound comprising formula (I): wherein R1 is an akylamino group or a group containing at least one aromatic group; R2 and R3 are independently an aliphatic group or hydrophobic group; R4 and R5 are independently H, a substituted or unsubstituted akyl group, an akenyl group, an acyl group, an aromatic group, polymer, a targeting group, or a detectable moiety; a, b, c, and d are independently an integer from 1 to 10; and pharmaceutically acceptable salts thereof.

Abstract: A PET/SPECT probe includes the following formula: P—1,—C wherein P is a EDB-FN targeting peptide, C is a PET/SPECT contrast agent; and L is an optional linker that covalently links the peptide to the contrast agent.

Abstract: A compound comprising formula (I): wherein R1 is an akylamino group or a group containing at least one aromatic group; R2 and R3 are independently an aliphatic group or hydrophobic group; R4 and R5 are independently H, a substituted or unsubstituted akyl group, an akenyl group, an acyl group, an aromatic group, polymer, a targeting group, or a detectable moiety; a, b, c, and d are independently an integer from 1 to 10; and pharmaceutically acceptable salts thereof.

Abstract: A molecular probe includes the following formula: P-L-C wherein P is a EDB-FN targeting peptide, C is a contrast agent; and L is a non-peptide linker that covalently links the peptide to the contrast agent.

Abstract: A composition includes a polysaccharide at least one retinoid linked to at least one monosaccharide subunit of the polysaccharide with a covalent linkage. The linkage being degradable by hydrolysis during digestion of the composition to provide controlled, delayed, and/or sustained delivery of the at least one retinoid upon enteral administration of the composition to a subject.

Abstract: A molecular probe includes the following formula: P-L-C wherein P is a EDB-FN targeting peptide, C is a contrast agent; and L is a non-peptide linker that covalently links the peptide to the contrast agent.

Abstract: A nanosized complex includes a nucleic acid and a compound comprising formula (I): wherein R1 is an alkylamino group or a group containing at least one aromatic group; R2 and R3 are independently an aliphatic group or hydrophobic group; R4 and R5 are independently H, a substituted or unsubstituted alkyl group, an alkenyl group, an acyl group, or an aromatic group, or a polymer, a targeting group, a detectable moiety, or a linker, or a combination thereof, and at least one of R4 and R5 includes a retinoid or retinoid derivative that targets and/or binds to an interphotoreceptor retinoid binding protein; a, b, c, and d are independently an integer from 1 to 10; and pharmaceutically acceptable salts thereof.

Abstract: A compound comprising formula (I): wherein R1 is an alkylamino group or a group containing at least one aromatic group; R2 and R3 are independently an aliphatic group or hydrophobic group; R4 and R5 are independently H, a substituted or unsubstituted alkyl group, an alkenyl group, an acyl group, or an aromatic group, or includes a polymer, a targeting group, or a detectable moiety, and at least one of R4 and R5 includes a targeting group that targets and/or binds to a retinal or visual protein; a, b, c, and d are independently an integer from 1 to 10; and pharmaceutically acceptable salts thereof.